Switch theme
Sign up to access all valuation multiples
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
2013
97
LTM Revenue $75.6M
LTM EBITDA n/a
$398M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Theravance has a last 12-month revenue of $75.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Theravance achieved revenue of $64.4M and an EBITDA of -$38.5M.
Theravance expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theravance valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $57.4M | $64.4M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$42.7M | -$38.5M | XXX | XXX | XXX |
| EBITDA Margin | -74% | -60% | XXX | XXX | XXX |
| Net Profit | $872M | -$55.2M | XXX | XXX | XXX |
| Net Margin | 1519% | -86% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Theravance's stock price is $9.
Theravance has current market cap of $437M, and EV of $398M.
See Theravance trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $398M | $437M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Theravance has market cap of $437M and EV of $398M.
Theravance's trades at 5.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Theravance's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Theravance and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $398M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | -10.3x | XXX | XXX | XXX |
| P/E | -7.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -33.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTheravance's NTM/LTM revenue growth is 30%
Theravance's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Theravance's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Theravance's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Theravance and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -60% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -29% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 58% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 166% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theravance acquired XXX companies to date.
Last acquisition by Theravance was XXXXXXXX, XXXXX XXXXX XXXXXX . Theravance acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Theravance founded? | Theravance was founded in 2013. |
| Where is Theravance headquartered? | Theravance is headquartered in United States of America. |
| How many employees does Theravance have? | As of today, Theravance has 97 employees. |
| Who is the CEO of Theravance? | Theravance's CEO is Mr. Rick E. Winningham. |
| Is Theravance publicy listed? | Yes, Theravance is a public company listed on NAS. |
| What is the stock symbol of Theravance? | Theravance trades under TBPH ticker. |
| When did Theravance go public? | Theravance went public in 2014. |
| Who are competitors of Theravance? | Similar companies to Theravance include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Theravance? | Theravance's current market cap is $437M |
| What is the current revenue of Theravance? | Theravance's last 12-month revenue is $75.6M. |
| What is the current EV/Revenue multiple of Theravance? | Current revenue multiple of Theravance is 5.3x. |
| What is the current revenue growth of Theravance? | Theravance revenue growth between 2023 and 2024 was 12%. |
| Is Theravance profitable? | Yes, Theravance is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
